Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income	$ 3,619.6	$ 3,322.0	$ 2,342.1
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	581.2	491.3	441.4
Depreciation and amortization expenses	181.3	148.3	125.6
Deferred income taxes	(536.5)	(275.9)	(154.6)
Losses (gains) on equity securities	0.6	149.1	(17.1)
Decrease in fair value of contingent consideration	(51.6)	(57.5)	(3.1)
Other non-cash items, net	8.4	11.8	14.4
Changes in operating assets and liabilities:
Accounts receivable, net	(84.1)	(358.6)	(274.7)
Inventories	(322.9)	(136.4)	(92.8)
Prepaid expenses and other assets	(545.7)	(326.4)	(91.8)
Accounts payable	48.7	120.8	31.9
Accrued expenses	429.4	542.5	305.4
Other liabilities	208.9	498.9	16.8
Net cash provided by operating activities	3,537.3	4,129.9	2,643.5
Cash flows from investing activities:
Purchases of available-for-sale debt securities	(3,786.5)	(692.7)	(528.2)
Sales and maturities of available-for-sale debt securities	839.1	920.0	499.3
Purchases of property and equipment	(200.4)	(204.7)	(235.0)
Sale of equity securities	95.1	0.0	0.0
Investment in equity securities and notes receivable	(31.0)	(47.8)	(77.0)
Payments related to finite-lived intangible assets	(58.0)	0.0	0.0
Payment to acquire ViaCyte, net of cash acquired	0.0	(295.9)	0.0
Net cash used in investing activities	(3,141.7)	(321.1)	(340.9)
Cash flows from financing activities:
Issuances of common stock under benefit plans	134.6	186.3	102.0
Repurchases of common stock	(427.6)	0.0	(1,425.4)
Payments in connection with common stock withheld for employee tax obligations	(226.1)	(172.0)	(135.9)
Payments on finance leases	(44.9)	(85.5)	(47.0)
Proceeds from finance leases and other financing activities	1.8	3.5	28.3
Net cash used in financing activities	(562.2)	(67.7)	(1,478.0)
Effect of changes in exchange rates on cash	26.9	(29.2)	(13.4)
Net (decrease) increase in cash, cash equivalents and restricted cash	(139.7)	3,711.9	811.2
Cash, cash equivalents and restricted cash—beginning of period	10,512.0	6,800.1	5,988.9
Cash, cash equivalents and restricted cash—end of period	10,372.3	10,512.0	6,800.1
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1,677.3	1,057.8	476.3
Cash paid for interest	43.1	52.3	56.3
Net payments due to CRISPR Therapeutics related to finite-lived intangible assets	$ 180.0	$ 0.0	$ 0.0